Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ODTX with free AI briefings, catalyst countdowns, and dilution alerts.

ODTX · Odyssey Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$433.1M Cash on Hand

34.4mo Cash Runway

5.3% Short Interest

$35.75 Analyst Target (4)

Follow ODTX by email Get an email when ODTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ODTX, unsubscribe in one click. Privacy

📣 What ODTX Says Is Next

second half of 2028 · “Second Quarter 2026 Financial Results As of June 30, 2026, Odyssey had cash, cash equivalents and marketable securities of $433.1 million, which are expected to fund Odyssey’s operations into the second half of 2028.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2027 · “OD-001 (RIPK2 scaffolding inhibitor): Initiate a Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab in the second half of 2026, with topline induction data from both studies expected in the second half of 2027.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2028 · “First Quarter 2026 Financial Results As of March 31, 2026, Odyssey had cash, cash equivalents and marketable securities of $175.7 million, which, together with the $288.7 million of net proceeds raised as part of its initial public offering, and concurrent private placement, are expected to fund Odyssey’s operations into the second half of 2028.”
Company press release, Jun 17, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Apr 2026 · Phase 2 · Recruiting · Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Sev
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
OD-07656	Ulcerative Colitis (UC)	Phase 2 · NCT06850727	Recruiting
PRV-002	Traumatic Brain Injury (TBI)	Phase 1 · NCT05033444	Completed

Also used in these trials (approved or third-party drugs, not ODTX's own candidates): Vedolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ODTX holds $433.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $37.8M/quarter from operations, an estimated runway of 34.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Cash runway 34 months
S-1 registration (Apr 2026) +8
Company says cash lasts into the second half of 2028 -10Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund our operating expenses and capital expenditures into the second half of 2028. 10-Q, Aug 2026

Recent financing filings on SEC EDGAR:

May 11, 2026 · Private placement (8-K Item 3.02) · 8-K
May 8, 2026 · Registered direct / best-efforts offering, $279M · 424B4
Apr 17, 2026 · S-1 registration · S-1
Jan 17, 2025 · S-1 registration · S-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ODTX files for a raise →

👥 Who Owns ODTX

Insiders 31.7% Other 5%+ holders 15.2% Institutions (61 holders) 53.1% Public and other holders 0%

Holder	Type	Shares	% of shares	As of
FMR LLC	Institution (13G, 5%+)	4,577,262	9.52%	2026-05-29
SR ONE CAPITAL MANAGEMENT, LLC 10% owner	Insider	3,794,883	7.90%	2026-05-11
TPG GP A, LLC Former 10% Owner	Insider	3,690,146	7.68%	2026-05-11
Jeito II S.L.P.	5%+ holder (13D)	3,690,145	7.68%	2026-05-08
Lightspeed Venture Partners XV-B (Ignite	5%+ holder (13G)	3,608,443	7.51%	2026-05-11
Lightspeed Management Company, L.L.C.	Institution (13F)	3,608,443	7.51%	2026-06-30
Nan (LN) Li Director	Insider	3,333,516	6.94%	2026-05-11
Dimension Capital II, L.P. Director	Insider	3,333,516	6.94%	2026-05-08
Dimension Management, L.P.	Institution (13G, 5%+)	3,333,516	6.94%	2026-05-08
Orbimed Advisors LLC.	Institution (13F)	3,001,198	6.24%	2026-06-30
Sanofi	Institution (13F)	1,991,918	4.14%	2026-06-30
Deerfield Management Company, L.P	Institution (13F)	1,046,139	2.18%	2026-06-30

Share count 48,058,527 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ODTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ODTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z